Pharma News India Weekly: Price Hikes, Trademark Tussles & Regulatory Crackdown
-20260328142758.jpg)
Pharma News India Weekly: Price Hikes, Trademark Tussles & Regulatory Crackdown (March 22-28, 2026)
Published: March 28, 2026
The third week after the semaglutide patent expiry saw the dust beginning to settle—but new battles emerged. From a high-profile trademark dispute between Novo Nordisk and Dr Reddy's over the "Olymvig" brand, to a nationwide crackdown on unapproved fixed-dose combinations, and the relentless pressure of raw material price hikes due to the West Asia conflict, the Indian pharmaceutical industry navigated another week of intense activity. As Biocon announced its leadership transition and major players recalibrated their GLP-1 strategies, the government tightened its grip on the distribution and promotion of weight-loss drugs.
Week at a Glance: Key Highlights
- Dr Reddy’s rebrands semaglutide from “Olymvig” to “Olymra” after court intervention
- API prices surge 200–300% in 15 days due to West Asia conflict
- CDSCO conducts nationwide inspections across 49 entities
- DCGI flags 26 unapproved fixed-dose combinations
- Biocon announces new CEO and avoids semaglutide market for now
- AIOCD confirms nationwide pharmacy bandh on May 11
⚖️ Trademark Tussle: Dr Reddy's Rebrands Semaglutide Amid Novo Nordisk Challenge
Date: March 26-27, 2026
The week began with a courtroom drama that highlighted the intense competition brewing in India's GLP-1 market. Danish drugmaker Novo Nordisk approached the Delhi High Court seeking to block Dr Reddy's Laboratories from launching its generic semaglutide under the brand name "Olymvig," arguing that it was phonetically and visually similar to its blockbuster drug Ozempic.
The Court's Intervention:
Justice Jyoti Singh, hearing the matter, expressed clear concern about the similarity. "I really will have to strain myself to find the difference—structurally, visually, and phonetically," she observed, noting that in a pharmaceutical context, such resemblance could lead to dangerous confusion among patients, doctors, and pharmacists.
The court directed Dr Reddy's to halt the rollout of the Olymvig brand, including manufacture and distribution, pending further hearing.
The Resolution:
By Friday, March 27, Dr Reddy's informed the court that it would voluntarily rebrand the product. The company proposed changing the name from "Olymvig" to "Olymra"—a minor alteration that satisfied Novo Nordisk's counsel, who indicated preliminary acceptance subject to conditions including discontinuation of the existing mark and withdrawal of the pending trademark application.
The Unresolved Inventory Question:
A more complex issue remained: what to do with the already manufactured stock of Olymvig? Novo Nordisk pushed for destruction or repackaging, arguing that allowing its sale would dilute the Ozempic brand. However, Justice Singh refused to order destruction, stating: "We are dealing with a product consumed by diabetic patients... There can be nothing worse than destroying it."
The court also expressed reservations about relabelling, questioning commercial viability: "Who is going to buy with this labelling?" The matter remains pending as the court balances commercial interests against patient access.
Background Context:
Novo Nordisk's patent on semaglutide expired on March 20, triggering a flood of generic launches. Dr Reddy's had already launched its injectable semaglutide under the brand name "Obeda" for diabetes, while "Olymvig" was intended as an additional brand. The Danish company argued that Ozempic is a "coined, well-known brand with global sales of over $63 billion over the past five years," and that allowing similar names would dilute its brand and risk confusion.
Raw Material Crisis: API Prices Soar 200-300%, Medicine Costs Set to Rise
Date: March 22-27, 2026
While courtroom battles made headlines, a more immediate crisis was unfolding across India's pharmaceutical manufacturing hubs. The West Asia conflict—now entering its fourth week—continued to choke the supply of critical raw materials, with prices skyrocketing by 200-300 per cent in just 15 days.
The Numbers Shows some market view:
- Paracetamol API: Jumped from ₹250 per kg to ₹450 per kg—an 80 per cent increase in a fortnight
- Glycerine: Up 64 per cent from December levels
- Ciprofloxacin: Turned 30 per cent costlier
- Packaging materials (PVC, aluminium foil): Up 40 per cent
- Solvents and intermediates: Increased 20-30 per cent
Himachal Pradesh Bears the Brunt:
The impact has been particularly severe for Himachal Pradesh's 650 pharmaceutical units, which produce nearly 25 per cent of India's medicines. According to the Himachal Drug Manufacturers Association (HDMA), manufacturing units that earlier functioned round-the-clock are now running single eight-hour shifts.
"Nearly 40 per cent of supply has already been cut, while raw material prices have increased by 150-200 per cent, making several production contracts financially unviable," said HDMA spokesperson Sanjay Sharma.
Production Under Threat:
The crisis extends beyond APIs to include:
- LPG shortage for industrial boilers — impacting sterilization and granulation processes
- Limited availability of solvents and excipients
- Packaging material shortages — aluminium, PET bottles, craft paper, glass containers
Price Impact on Consumers:
Industry representatives warn that if the situation persists, medicine prices could rise by 20-25 per cent in the coming weeks. Punjab Chemist Association president Surinder Duggal, representing 27,400 chemists, cautioned that commonly used medicines including paracetamol, ibuprofen, and diabetes drugs like metformin are likely to see price increases as stocks decline.
Industry Demands Government Intervention:
HDMA has written to the Ministry of Chemicals and Fertilizers and the Department of Pharmaceuticals, seeking:
- Formation of an emergency task force
- Enforcement of the Essential Commodities Act, 1956 to stabilise supplies and control costs
- Price caps on APIs, solvents, excipients, and packaging materials
- Strict monitoring of stock levels to curb hoarding
CDSCO Tightens Grip on GLP-1 Drug Distribution Chain
Date: March 27, 2026
With cheaper generic versions of semaglutide flooding the market, India's drug regulator moved decisively to prevent misuse. The Central Drugs Standard Control Organisation issued a comprehensive advisory directing state drug controllers to strengthen monitoring of the end-to-end supply chain of GLP-1-based weight-loss drugs.
Key Directives:
- States must ensure that manufacture, import, distribution, retail/wholesale sales, and dispensing occur only through authorised channels
- All stakeholders must strictly adhere to approved indications and labelling
- Any diversion, leakage into unauthorized channels, or promotions influencing supply practices to be viewed seriously
- State authorities to actively monitor print, electronic, digital, social media, and outdoor platforms for non-compliant advertisements or surrogate promotional activities
Enforcement Actions:
Over the past several weeks, CDSCO—in coordination with state licensing authorities—conducted a comprehensive nationwide enforcement campaign. Coordinated audits and inspections were carried out across multiple regions, covering 49 entities including online pharmacy warehouses, drug wholesalers, retailers, wellness and slimming clinics.
Legal Framework:
The regulator warned that violations would attract action under the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, and the Drugs and Cosmetics Act, 1940. Where necessary, state drug controllers were asked to coordinate with the Advertising Standards Council of India (ASCI) for effective enforcement.
The Context:
The crackdown comes amid growing concerns about the misuse of GLP-1 drugs for cosmetic weight loss. Earlier in March, the DCGI had already banned surrogate advertising for these drugs. With nearly a dozen generic versions already in the market and about 30 more expected, the regulator is clearly determined to ensure patient safety remains paramount.
Unapproved Fixed-Dose Combinations Under Scanner
Date: March 26, 2026
In a separate regulatory action, the Drugs Controller General of India directed state drug authorities to prevent the manufacture, sale, and distribution of 26 unapproved fixed-dose combination drugs found to be manufactured by 19 pharmaceutical firms across Baddi, Solan, Paonta Sahib, and Kangra in Himachal Pradesh.
The Violation:
These FDCs—which combine two or more active drugs in a single dosage form—were being manufactured and sold without the requisite central approval. Under Rule 83 of the New Drugs and Clinical Trials (NDCT) Rules, 2019, manufacturers must obtain permission for a new drug from the central licensing authority (DCGI) before applying for a manufacturing licence.
The Drugs in Question:
The unapproved FDCs were assigned to treat common ailments including cough, hair loss, pain, diabetes, vitamin deficiency, nerve pain, fluid retention, asthma, and acid indigestion.
Regulatory Concern:
"The presence of new drugs in the supply chain is a matter of serious concern posing potential risk to public health and safety. It also indicates non-compliance with the provisions of the Drugs and Cosmetics Act, 1940," the DCGI stated in its communication.
State Drugs Controller Dr Manish Kapoor confirmed that manufacturers have been asked to submit the permissions taken for manufacturing these FDCs, with action-taken reports to be submitted to the DCGI.
Biocon's New Chapter: Tambe Takes Charge, Stays Out of India's Semaglutide Rush
Date: March 27-28, 2026
Bengaluru-based biopharmaceutical major Biocon announced a significant leadership transition, appointing Shreehas Tambe as Chief Executive Officer and Managing Director, effective April 1, 2026. Kedar Upadhye was appointed as Chief Financial Officer.
The Strategic Pivot:
In his first interview after the appointment, Tambe outlined a three-pronged strategy focused on people, technology, and patient access—while signalling a shift from cost leadership to capability-led growth.
Semaglutide: A Calculated Wait:
Perhaps the most notable strategic decision revealed during the week was Biocon's choice to stay out of India's crowded semaglutide market—at least for now.
"We have not looked at semaglutide as a priority for India at this time because there are plenty of options in India at this stage," Tambe told ET. "We want the dust to settle down before we move this forward... but not in the near future."
Instead, Biocon is prioritising overseas opportunities for semaglutide, with initial launches planned in Canada, Brazil, and the Middle East. The company is also scaling up liraglutide—a peptide-based drug to treat type-2 diabetes—for which it already has approvals in Europe and the UK.
The Integration Play:
The leadership transition is part of the full integration of Biocon Biologics as a wholly-owned subsidiary of Biocon Limited, creating a simplified and unified corporate structure. The combined entity now spans biosimilars and generics, with a strong presence in diabetes, obesity, oncology, and immunology.
New Horizons:
Beyond its core areas, Biocon is exploring adjacencies including ophthalmology and antibody-drug conjugates. "We have a blockbuster in the ophthalmology space and are preparing for its US launch shortly... there is a large opportunity in antibody-drug conjugates," Tambe said.
Office of AI:
The company is establishing an "Office of AI"—what Tambe calls augmented intelligence—to drive productivity, unlock insights, and improve the speed and quality of decision-making across the organisation.
Hetero Launches Generic Semaglutide Overseas, Awaits Indian Approval
Date: March 27, 2026
While Biocon chose to wait, Hetero Pharmaceuticals moved aggressively to launch its generic semaglutide portfolio in overseas markets even as it awaits regulatory approvals in India.
Global Rollout:
The launch represents the beginning of a strategic, multi-year global rollout across more than 75 countries. Initial launches are underway in Africa, Asia, and West Asia, with further rollouts planned subject to regulatory approvals. The injectable semaglutide therapies will be marketed under the brand names Truglyx, Rolmodl, and Moto G across markets.
Delivery Device:
The portfolio will be available in multi-dose disposable pen devices designed in line with innovator formats, across multiple dose strengths including 0.25 mg, 0.5 mg, 1 mg, 2 mg, 1.7 mg, and 2.4 mg—supporting both type-2 diabetes and weight management.
Indian Approval Pending:
Hetero is currently awaiting approval from India's national regulator following the completion of clinical trials in type-2 diabetes and obesity. Launch in India is anticipated post regulatory approvals.
AIOCD Announces Nationwide Pharmacy Bandh on May 11
Date: March 22-28, 2026 (reported earlier, continues to resonate)
The All India Organisation of Chemists and Druggists formalized its nationwide strike—a "National Pharmacy Bandh"—scheduled for May 11, 2026. The decision was finalized during the national executive committee meeting in Udaipur on March 15, with the date moved from April 15 to avoid clashing with Assembly elections.
Key Demands:
- Withdrawal of government notifications GSR 220(E) and GSR 817(E), which AIOCD argues create loopholes for e-pharmacies to bypass the Drugs and Cosmetics Act
- Regulation of online pharmacies operating in a regulatory vacuum
- Opposition to doorstep delivery of medicines proposed by government agencies
- Standardized pricing environment to counter deep discounts offered by large chain pharmacies
The Stakes:
The bandh is expected to affect more than 12.40 lakh brick-and-mortar chemists across India. AIOCD General Secretary Rajiv Singhal expressed "deep frustration over the government's lackadaisical attitude toward regulating online pharmacies," arguing these platforms "encourage self-medication and contribute to the global threat of antimicrobial resistance."
Operational Exemption:
Emergency pharmacies located within hospitals are expected to remain operational to ensure patient safety.
West Asia Crisis: Four Weeks In, Exports to Region Come to Near-Halt
Date: March 26-28, 2026
Four weeks into the widening West Asia conflict, Indian exporters are grappling with a compounding crisis that has brought regional trade to a virtual standstill.
Export Freeze:
"As much as 16 per cent of our exports go to West Asia but since March 1 exports to the region have virtually come to a standstill as no shipments are being dispatched and there is almost negligible air cargo," said Pankaj Chadha, Chairman, Engineering Export Promotion Council. The Strait of Hormuz—the primary gateway to the region—has been effectively blocked.
Payment Crisis:
Exporters are facing a liquidity crunch due to blocked payments. "Our payments are stuck as money is not coming from West Asia. The importers claim that their economies are badly hurt so there is not much buying. They do not have any money to pay us," said Sanjay Jain, a major exporter of garments and textiles.
Cost Escalation:
Shipments to other destinations being routed through the Cape of Good Hope have also taken a beating due to increased shipment costs of up to $2,000 per container.
Input Cost Surge:
For footwear manufacturers, petroleum-based inputs including rubber, polyurethanes, and synthetic linings have seen price increases of 20-30 per cent, leading to at least 10 per cent increase in total production cost.
NPPA Allows 0.64% Price Hike for Essential Drugs
Date: March 25, 2026
The National Pharmaceutical Pricing Authority announced that manufacturers may increase prices of scheduled formulations included in the National List of Essential Medicines by 0.64 per cent, based on the annual change in the Wholesale Price Index.
What It Means:
- The increase applies to approximately 900 formulations including pain relievers, antibiotics, and chronic disease treatments
- Manufacturers can raise maximum retail prices without prior approval
- The revision is based on WPI increase of 0.64956 per cent during calendar year 2025 over 2024
Industry Disappointment:
The marginal hike comes at a time when spiralling input costs due to the West Asia conflict have severely squeezed sector margins. Industry representatives expressed disappointment, noting that prices of key APIs and solvents have risen substantially—with some increasing 30-35 per cent on average—and the 0.64 per cent hike does little to offset these pressures.
India-U.S. Trade Deal: Gaps Remain on Pulses, Tariff Staging
Date: March 27, 2026
As India and the U.S. continue negotiations on an interim trade deal, a U.S. official indicated that "we're not that far off from finalising the interim trade deal, but some gaps remain."
Key Gaps:
- Pulses: India is seeking to safeguard its market for this agricultural commodity, while the U.S. wants greater access
- Tariff staging: Washington is seeking reduced staging—speeding up phased reduction of tariffs
Political Sensitivity:
Agriculture remains a deeply sensitive issue for both countries. Last month, a White House "fact sheet" included "certain pulses" on a list of items India would cut tariffs on—a claim that was later retracted after political furore in India.
The Bigger Picture:
The ongoing Special 301 investigations launched by the U.S. against India and other countries for excess manufacturing capacity and forced labour continue to cast a shadow over trade discussions.
Research Highlights
Metformin's Brain Pathway Discovered:
A study published in Science Advances uncovered that metformin—the first-line treatment for diabetes for over 60 years—regulates blood sugar by acting on the brain, specifically targeting the Rap1 protein in the ventromedial hypothalamus. The finding opens the door to developing new diabetes treatments that directly target this brain pathway.
De-prescribing Safe for Elderly:
An analysis of 15 studies involving over 33,000 participants found that de-prescribing preventive medications among old, frail adults did not increase the risk of death, hospitalisation, or major heart-related events. The findings, published in BMC Geriatrics, suggest that stopping certain medications in patients with limited life expectancy may be safe.
Key Data Points Summary
MetricValueParacetamol API price increase (15 days)80% (₹250 to ₹450/kg)Glycerine price increase64%Ciprofloxacin price increase30%Packaging material price increase40%Himachal pharma units affected650Unapproved FDCs flagged26Entities inspected for GLP-1 misuse49AIOCD bandh dateMay 11, 2026NLEM price hike (April 1)0.64%
Frequently Asked Questions
What are the top pharmaceutical trends for 2026?
Key trends include: 1) GLP-1 market explosion with multiple generic entrants following patent expiry, 2) Intensified regulatory scrutiny on drug promotion and distribution, 3) Geopolitical supply chain disruptions driving raw material cost inflation, 4) Trademark disputes as generic players compete for market share, 5) Consolidation and leadership transitions in major pharma companies, and 6) Growing focus on biosimilars and complex generics.
What are the latest pharma news updates this week?
Major developments include: Dr Reddy's rebranding its semaglutide drug after trademark dispute with Novo Nordisk, CDSCO crackdown on GLP-1 drug distribution across 49 entities, raw material price surges of 200-300% threatening medicine price hikes, Biocon appointing Shreehas Tambe as CEO while staying out of India's semaglutide rush, and AIOCD announcing a nationwide pharmacy strike on May 11.
What is happening in the pharmaceutical industry this week?
The industry is navigating multiple challenges: raw material costs are skyrocketing due to the West Asia conflict, forcing production cuts and potential price hikes; regulatory authorities are conducting nationwide audits to prevent GLP-1 drug misuse; a high-profile trademark battle between Dr Reddy's and Novo Nordisk was resolved with a voluntary rebrand; and traditional chemists are preparing for a nationwide strike against e-pharmacies.
Where can I find all weekly pharma industry news?
For comprehensive weekly updates on the Indian pharmaceutical industry, including market trends, policy changes, and corporate developments, visit GreenCrossIndia.com/blog.
What is Zydus's latest news this week?
While Zydus did not feature prominently in this week's news, the company had previously launched its generic semaglutide injection under brand names Semaglyn, Mashema, and Alterme following the March 20 patent expiry, with a reusable pen device offering dosing flexibility. The company continues to focus on its innovative drug delivery systems as a differentiator in the crowded GLP-1 market.
How is the West Asia conflict affecting Indian pharma?
The conflict has caused API prices to surge 200-300% in 15 days, with paracetamol up 80%, glycerine 64%, and solvents 20-30%. Production at 650 Himachal units has been cut to single shifts, and manufacturers warn of 20-25% medicine price rises if the situation persists. LPG shortages for boilers and packaging material shortages are compounding the crisis.
What is the status of GLP-1 regulation in India?
CDSCO has launched a nationwide crackdown on GLP-1 drug misuse, conducting audits at 49 entities including online pharmacies, wholesalers, and wellness clinics. States have been directed to ensure distribution occurs only through authorised channels, monitor advertisements, and take strict action against violations under the Drugs and Cosmetics Act and Drugs and Magic Remedies Act.
Disclaimer and References
This article is compiled for informational purposes based on publicly available pharmaceutical industry updates, market reports, and news sources including Economic Times, Business Line, Financial Express, Mint, Pharmarack data, and global pharma publications. It does not constitute medical, legal, or financial advice. Readers are advised to verify information from official sources before making decisions.GreenCross India assumes no liability for errors, omissions, or reliance on this content. Prescription drugs require proper medical supervision.